SCHEMBL6800436

SCHEMBL6800436

O=S(=O)(NCCO)c1ccc(N2CCC3(CC2)OCCO3)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
SMN1; SMN2 Q16637 4/20 0.48
LMNA P02545 3/20 0.48
MAPK1 P28482 2/20 0.48
NPC1 O15118 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CYP2C19 P33261 2/20 0.45
CYP3A4 P08684 1/20 0.45
PKM P14618 2/20 0.44
KDM4E B2RXH2 1/20 0.43
HTR7 P34969 1/20 0.42
GAA P10253 2/20 0.42
MEN1 O00255 1/20 0.42
HBB P68871 1/20 0.42
KMT2A Q03164 1/20 0.42
POLB P06746 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6795927 0.85 ALDH1A1 (0.75) ALDH1A1SMN1; SMN2LMNAMAPK1NPC1
SCHEMBL6799370 0.81 SMN1; SMN2 (0.67) ALDH1A1SMN1; SMN2LMNAMAPK1NPC1
SCHEMBL6806953 0.81 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2LMNAMAPK1NPC1
SCHEMBL17893806 0.80 PKM (0.49) ALDH1A1SMN1; SMN2LMNAMAPK1MAPT
SCHEMBL6802861 0.79 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2LMNAMAPTHTT
SCHEMBL6441839 0.78 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2LMNACYP2C19PKM
SCHEMBL6800812 0.77 MAPT (0.49) ALDH1A1SMN1; SMN2LMNAMAPK1MAPT
SCHEMBL10473148 0.76 KMT2A (0.50) ALDH1A1PKMKDM4EKMT2APOLB
SCHEMBL10394428 0.76 AKR1C3 (0.54) ALDH1A1PKMKDM4EPOLBLGMN
SCHEMBL6801306 0.76 KDM4E (0.55) ALDH1A1LMNAPKMKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6743787-B2 FOR THERAPY OF METABOLIC DISORDERS MEDIATED BY INSULIN RESISTANCE OR HYPERGLYCEMIA IN A MAMMAL WYETH 2004-06-01 US disclosed
US-20030027795-A1 N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists WYETH 2003-02-06 US disclosed
US-6444685-B1 THERAPY FOR METABOLISM DISEASES; DIETETICS; ANTIDIABETIC AGENTS WYETH 2002-09-03 US disclosed
US-20020028797-A1 N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists AMERICAN HOME PRODUCTS CORPORATION 2002-03-07 US disclosed
WO-2002006274-A1 N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS WYETH (US) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030027795-A1 N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists ADRB3, ADRB1, ADRB2 ALDH1A1 2253/4885SMN1; SMN2 2820/4885LMNA 1552/4885
US-20020028797-A1 N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists ADRB3, ADRB1, ADRB2 ALDH1A1 1800/4885SMN1; SMN2 2852/4885LMNA 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.